Mankind Pharma licenses insulin degludec and insulin degludec–aspart combination for India
- nuaxia
- 20 ore fa
- Tempo di lettura: 2 min
The exclusive agreement expands Mankind Pharma's injectable diabetes portfolio with two long-acting insulin analogues while strengthening its strategy of in-licensing innovative therapies for the Indian market.
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. for the commercialisation of insulin degludec and the insulin degludec + insulin aspart combination in India. The transaction broadens Mankind Pharma's presence in injectable diabetes therapies, although financial terms were not disclosed and both products remain subject to regulatory approval before launch in India.
Field | Content |
Alert Type | Deal |
Companies | Mankind Pharma Limited; Chongqing Chenan Biopharmaceutical Co., Ltd. |
Deal Type | Exclusive in-licensing and marketing agreement |
Asset or Company | Insulin degludec and insulin degludec + insulin aspart combination |
Therapy Area(s) | Diabetes; Endocrinology |
Technology or Modality | Recombinant insulin analogues (long-acting basal insulin and basal/rapid-acting insulin combination) |
Deal Value | Financial terms were not disclosed. Mankind Pharma has secured exclusive commercialisation and marketing rights for India. (BSE India) |
Development Stage | Phase III completed in China; regulatory approval in India pending. (ETPharma.com) |
Geography | India |
What Happened | On 20 August 2026, Mankind Pharma announced an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical to commercialise insulin degludec and the insulin degludec + insulin aspart combination in India. The products are intended to expand Mankind's injectable diabetes portfolio, but both remain subject to approval by India's Central Drugs Standard Control Organisation (CDSCO) before they can be launched commercially. (BSE India) |
Why It Matters | The agreement strengthens Mankind Pharma's position in the growing injectable diabetes market by adding long-acting insulin analogues to its chronic care portfolio. It also reflects the company's broader strategy of accessing innovative products through international licensing partnerships rather than in-house development. (BSE India) |
Supporting Context | Insulin degludec is an ultra-long-acting basal insulin, while the insulin degludec + insulin aspart combination provides both basal and mealtime glucose control in a single formulation. The products are alternatives to Novo Nordisk's Tresiba and Ryzodeg and have completed Phase III studies in China. (ETPharma.com) |
Strategic Rationale | Mankind Pharma gains two established insulin analogues that complement its existing diabetes portfolio and support its ambition to expand in injectable therapies. For Chongqing Chenan, the agreement provides a commercial route into the Indian market through an established domestic pharmaceutical company. (BSE India) |
Potential Impact | If approved by the CDSCO, the products could strengthen Mankind Pharma's competitive position in India's diabetes market and broaden treatment options for patients requiring injectable insulin. The commercial impact will depend on regulatory approval, pricing and market uptake. (Business Standard) |
Key Takeaway | The agreement expands Mankind Pharma's injectable diabetes portfolio with two late-stage insulin analogues while reinforcing its strategy of building its chronic care business through global in-licensing partnerships. |
What to Watch | CDSCO regulatory review, launch timelines in India and whether Mankind Pharma continues to expand its diabetes portfolio through additional licensing agreements with Chinese biotechnology companies. (Business Standard) |
Primary Source | |
Relevant Date | 20 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti